Research programme: CRAC ion channel inhibitors - Madrigal Pharmaceuticals

Drug Profile

Research programme: CRAC ion channel inhibitors - Madrigal Pharmaceuticals

Latest Information Update: 05 Aug 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Synta Pharmaceuticals
  • Developer Madrigal Pharmaceuticals
  • Class Small molecules
  • Mechanism of Action Calcium channel antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Immunological disorders
  • Research Inflammation

Most Recent Events

  • 22 Jul 2016 Madrigal Pharmaceuticals merged with Synta Pharmaceuticals and the combined company is now called Madrigal Pharmaceuticals
  • 15 Mar 2016 Synta Pharmaceuticals and PRCL Research enter into a license agreement (Synta Pharmaceuticals, 10-K, March 2016)
  • 05 May 2011 Preclinical development is ongoing
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top